Business Wire

Lineage Unveils the Global Food Chain Innovation Challenge to Combat Food Waste

3.7.2024 10:00:00 EEST | Business Wire | Press release

Share

Lineage, the world’s largest global temperature-controlled warehouse REIT, today announced the launch of its pioneering initiative, the Food Chain Innovation Challenge. This aspiring global competition invites students and startups to develop and pitch groundbreaking solutions aimed at tackling one of the world’s most pressing issues: food waste, particularly postharvest losses.

The challenge will convene bright minds at three major events across the globe: London, United Kingdom on November 14; Amsterdam, The Netherlands on November 19; and San Francisco, United States also on November 19. Participants are called to present their innovative solutions that can empower different regions of the world – from mature to emerging and developing markets – to mitigate postharvest food spoilage through affordable and scalable methods, thereby enhancing food security, quality, safety, and market access.

Winners from each regional event will win a cash prize. Additionally, an overall winner will be selected from the regional winners and announced in December. The grand prize winner will receive entry into an incubator program tailored to help them further refine their business development skills and scale their solution effectively.

At the events, participants will be asked to pitch their ideas to a panel of esteemed judges, concentrating their efforts in one of four specific areas:

  • Reducing food waste: Introduce technologies and strategies to diminish food loss from farm to market.
  • Innovative food preservation techniques: Propose novel methods that enhance food longevity and reduce spoilage.
  • Access to nutritious food: Improve the logistics of food distribution to enhance the availability of nutritious foods in underserved areas.
  • Data-driven insights and analytics: Employ analytics and IoT to optimize supply chains and reduce waste.

“According to the UN Environment Programme’s Food Waste Index Report 2024, the latest data from 2022, shows 1.05 billion tonnes of food went to waste — an amount sufficient to nourish billions. This reality is stark, especially considering that over 783 million individuals globally suffer from undernourishment. By reducing food waste, we can significantly enhance global food security and address hunger,” said Greg Lehmkuhl, President and CEO of Lineage, “At Lineage, we are dedicated to spearheading innovation across the global food supply chain. Through our Food Chain Innovation Challenge, we are seeking to cultivate solutions that not only tackle food waste but also advance sustainable development. We are eager to witness the emergence of these new ideas and their evolution into practical, impactful strategies.”

The Food Chain Innovation Challenge underscores Lineage's commitment to sustainability, improving the global management of food storage, transport, and distribution. If you're interested in participating, apply here. For a glimpse into the 2023 Hackathon, the predecessor to The Food Chain Innovation Challenge, held in Amsterdam watch this video. Also, hear insights from last year's winner to get inspired and understand the impact of winning this prestigious challenge.

About Lineage

Lineage, Inc. is the world’s largest global temperature-controlled warehouse REIT with a network of over 480 strategically located facilities totaling over 84.1 million square feet and 3.0 billion cubic feet of capacity across countries in North America, Europe, and Asia-Pacific. Coupling end-to-end supply chain solutions and technology, Lineage partners with some of the world’s largest food and beverage companies to help increase distribution efficiency, advance sustainability, minimize supply chain waste, and, most importantly, feed the world. (onelineage.com)

View source version on businesswire.com: https://www.businesswire.com/news/home/20240703425894/en/

Contacts

Nina Bosch
+31 6 81938713
nbosch@onelineage.com

Christina Wiese
734-608-1855
cwiese@onelineage.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye